Trial Profile

Safety, Immunogenicity and Efficacy of Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pfs25 Pfs230 malaria vaccine MVI (Primary) ; Artemether/lumefantrine; AS01B; GSK 137173A; Hepatitis A vaccine inactivated; Meningococcal vaccine groups A C Y W-135 conjugate; Typhoid vaccine Vi-polysaccharide
Indications Falciparum malaria
Focus Adverse reactions; Pharmacodynamics

22 Mar 2023 Status changed from active, no longer recruiting to completed.
17 Nov 2021 Planned End Date changed from 31 Oct 2021 to 31 Oct 2022.
17 Feb 2021 Planned primary completion date changed from 31 Aug 2021 to 31 Oct 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com